Audentes Therapeutics (NASDAQ: BOLD) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Audentes Therapeutics to similar businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.
This is a breakdown of recent ratings and target prices for Audentes Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Audentes Therapeutics Competitors||765||3044||11230||227||2.72|
Audentes Therapeutics presently has a consensus target price of $26.17, indicating a potential upside of 1.38%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.09%. Given Audentes Therapeutics’ rivals higher possible upside, analysts clearly believe Audentes Therapeutics has less favorable growth aspects than its rivals.
Volatility & Risk
Audentes Therapeutics has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500. Comparatively, Audentes Therapeutics’ rivals have a beta of 6.62, meaning that their average share price is 562% more volatile than the S&P 500.
This table compares Audentes Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Audentes Therapeutics Competitors||-5,489.25%||-451.68%||-42.65%|
Institutional & Insider Ownership
77.1% of Audentes Therapeutics shares are held by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 47.3% of Audentes Therapeutics shares are held by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Audentes Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Audentes Therapeutics||N/A||-$73.43 million||-7.27|
|Audentes Therapeutics Competitors||$260.16 million||$66.28 million||-6.36|
Audentes Therapeutics’ rivals have higher revenue and earnings than Audentes Therapeutics. Audentes Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
What are top analysts saying about Audentes Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics Inc. and related companies.